Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You should be fully active or able to do light work (ECOG score 0 or 1).
- Your doctor must expect you to live at least 3 more months.
- You must have small cell lung cancer confirmed by biopsy or lab tests.
- You must have had at least one prior treatment and your cancer has returned.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ZG006 for people with advanced small cell lung cancer or a type of neuroendocrine cancer. It aims to find the best dose and see if it helps shrink tumors.
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a new drug called ZG006 for people with small cell lung cancer that has not responded to or can no longer tolerate standard treatments. The goal is to find the best dose and see if it can help shrink or control the cancer.
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.